JP7008337B2 - ヒト機能性角膜内皮細胞およびその応用 - Google Patents

ヒト機能性角膜内皮細胞およびその応用 Download PDF

Info

Publication number
JP7008337B2
JP7008337B2 JP2018561784A JP2018561784A JP7008337B2 JP 7008337 B2 JP7008337 B2 JP 7008337B2 JP 2018561784 A JP2018561784 A JP 2018561784A JP 2018561784 A JP2018561784 A JP 2018561784A JP 7008337 B2 JP7008337 B2 JP 7008337B2
Authority
JP
Japan
Prior art keywords
cell
cells
corneal endothelial
negative
phenotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018561784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510509A (ja
JP2019510509A5 (https=
Inventor
茂 木下
淳爾 羽室
千恵 外園
盛夫 上野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KYOTO PREFECTURAL UNIVERSITY OF MEDICINE
Original Assignee
KYOTO PREFECTURAL UNIVERSITY OF MEDICINE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58261691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7008337(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by KYOTO PREFECTURAL UNIVERSITY OF MEDICINE filed Critical KYOTO PREFECTURAL UNIVERSITY OF MEDICINE
Publication of JP2019510509A publication Critical patent/JP2019510509A/ja
Priority to JP2020022800A priority Critical patent/JP7453669B2/ja
Priority to JP2020022799A priority patent/JP6954682B2/ja
Publication of JP2019510509A5 publication Critical patent/JP2019510509A5/ja
Application granted granted Critical
Publication of JP7008337B2 publication Critical patent/JP7008337B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3808—Endothelial cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2018561784A 2016-02-15 2017-02-14 ヒト機能性角膜内皮細胞およびその応用 Active JP7008337B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020022800A JP7453669B2 (ja) 2016-02-15 2020-02-13 ヒト機能性角膜内皮細胞およびその応用
JP2020022799A JP6954682B2 (ja) 2016-02-15 2020-02-13 ヒト機能性角膜内皮細胞およびその応用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
JP2016026423 2016-02-15
JP2016026426 2016-02-15
JP2016026423 2016-02-15
JP2016026424 2016-02-15
JP2016026425 2016-02-15
JP2016026424 2016-02-15
JP2016026425 2016-02-15
JP2016026426 2016-02-15
JP2016077450 2016-04-07
JP2016077450 2016-04-07
PCT/JP2017/005386 WO2017141926A1 (en) 2016-02-15 2017-02-14 Human functional corneal endothelial cell and application thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020022800A Division JP7453669B2 (ja) 2016-02-15 2020-02-13 ヒト機能性角膜内皮細胞およびその応用
JP2020022799A Division JP6954682B2 (ja) 2016-02-15 2020-02-13 ヒト機能性角膜内皮細胞およびその応用

Publications (3)

Publication Number Publication Date
JP2019510509A JP2019510509A (ja) 2019-04-18
JP2019510509A5 JP2019510509A5 (https=) 2020-04-02
JP7008337B2 true JP7008337B2 (ja) 2022-02-10

Family

ID=58261691

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2018561784A Active JP7008337B2 (ja) 2016-02-15 2017-02-14 ヒト機能性角膜内皮細胞およびその応用
JP2020022799A Active JP6954682B2 (ja) 2016-02-15 2020-02-13 ヒト機能性角膜内皮細胞およびその応用
JP2020022800A Active JP7453669B2 (ja) 2016-02-15 2020-02-13 ヒト機能性角膜内皮細胞およびその応用
JP2023205812A Pending JP2024019306A (ja) 2016-02-15 2023-12-06 ヒト機能性角膜内皮細胞およびその応用
JP2025182944A Pending JP2026021433A (ja) 2016-02-15 2025-10-29 ヒト機能性角膜内皮細胞およびその応用
JP2025182943A Pending JP2026012325A (ja) 2016-02-15 2025-10-29 ヒト機能性角膜内皮細胞およびその応用

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2020022799A Active JP6954682B2 (ja) 2016-02-15 2020-02-13 ヒト機能性角膜内皮細胞およびその応用
JP2020022800A Active JP7453669B2 (ja) 2016-02-15 2020-02-13 ヒト機能性角膜内皮細胞およびその応用
JP2023205812A Pending JP2024019306A (ja) 2016-02-15 2023-12-06 ヒト機能性角膜内皮細胞およびその応用
JP2025182944A Pending JP2026021433A (ja) 2016-02-15 2025-10-29 ヒト機能性角膜内皮細胞およびその応用
JP2025182943A Pending JP2026012325A (ja) 2016-02-15 2025-10-29 ヒト機能性角膜内皮細胞およびその応用

Country Status (6)

Country Link
US (3) US20190083543A1 (https=)
EP (2) EP3416658B1 (https=)
JP (6) JP7008337B2 (https=)
ES (1) ES2947826T3 (https=)
PL (1) PL3416658T3 (https=)
WO (1) WO2017141926A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2858173C (en) 2011-12-06 2023-09-26 Advanced Cell Technology, Inc. Method of directed differentiation producing corneal endothelial cells, compositions thereof, and uses thereof
EP3416658B1 (en) 2016-02-15 2023-03-22 Kyoto Prefectural Public University Corporation Human functional corneal endothelial cell and application thereof
CN107629999A (zh) * 2017-10-18 2018-01-26 清华大学深圳研究生院 一种增加间充质干细胞外泌体产生及分泌的方法
US12350294B2 (en) 2018-01-16 2025-07-08 Keio University Medium comprising serum replacement, IGF1, STAT3 activator and adrenal gland hormone without BFGF or rock inhibitor for producing corneal endothelial substitute cells from iPS cells and a method thereof
EP3893904A4 (en) * 2018-12-12 2022-08-17 The Johns Hopkins University GENERATION AND CRYOPRESERVATION OF CLINICAL-QUALITY CORNEAL EDDELLIAL CELLS FROM PLURIPOTENTIC STEM CELLS
KR102446567B1 (ko) * 2019-04-17 2022-09-26 연세대학교 산학협력단 각막 내피 세포의 기능 부전 진단용 바이오마커
JP2020200296A (ja) * 2019-06-13 2020-12-17 久貴 藤本 角膜内皮障害の予防及び／又は治療のための薬剤
US12230397B2 (en) * 2019-08-21 2025-02-18 Case Western Reserve University Assessment of endothelial cells and corneas at risk from ophthalmological images
WO2021172554A1 (ja) 2020-02-27 2021-09-02 京都府公立大学法人 ヒト機能性角膜内皮細胞およびその応用
WO2022025239A1 (ja) * 2020-07-31 2022-02-03 学校法人同志社 角膜内皮細胞注入療法の治療効果増強法
AU2021366805B2 (en) * 2020-10-22 2025-04-24 Kyoto Prefectural Public University Corporation A storage method of human corneal endothelial cells and/or human corneal endothelial precursor cells
CN112538458B (zh) * 2020-11-26 2025-10-31 北京孟眸生物科技有限公司 用于重编程细胞的方法
US20240350552A1 (en) 2021-07-07 2024-10-24 Cellusion Inc. Therapeutic composition containing corneal endothelium replacement cells
WO2023282338A1 (ja) 2021-07-07 2023-01-12 株式会社セルージョン 細胞播種剤及び細胞移植用基材
CN114507635B (zh) * 2022-01-24 2024-03-22 上海纽仁生物医药科技有限公司 一种动物神经系统内皮细胞单细胞的分离方法
WO2023190941A1 (ja) * 2022-03-31 2023-10-05 学校法人同志社 培養由来成分を含まない角膜内皮細胞製剤及びその製造法
WO2023230171A2 (en) * 2022-05-24 2023-11-30 University Of Pittsburgh - Of Thecommonwealth System Of Highereducation Compositions and methods of treating corneal scarring
EP4655392A2 (en) * 2023-01-27 2025-12-03 Universiteit Maastricht Methods for selecting cultured corneal endothelial cells
WO2024182683A1 (en) * 2023-03-01 2024-09-06 The Regents Of The University Of California Rapid, accurate, and reproducible screening of endothelial cell morphology in diseased and healthy corneas
KR20250024502A (ko) * 2023-08-11 2025-02-18 재단법인 아산사회복지재단 분화 유도된 각막 내피 세포를 포함하는 각막 질환 예방 또는 치료용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013051722A1 (ja) 2011-10-06 2013-04-11 学校法人 慶應義塾 角膜内皮細胞の製造方法
WO2015016371A1 (ja) 2013-07-30 2015-02-05 京都府公立大学法人 角膜内皮細胞マーカー

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
JP3421217B2 (ja) 1995-11-20 2003-06-30 麒麟麦酒株式会社 Ｒｈｏ標的タンパク質Ｒｈｏキナーゼ
AU9646198A (en) 1997-10-22 1999-05-10 Nippon Shinyaku Co. Ltd. Isoquinoline derivative and drug
WO1999061403A1 (en) 1998-05-25 1999-12-02 Santen Pharmaceutical Co., Ltd. Novel vinylbenzene derivatives
EP1020534B2 (en) 1998-11-09 2011-01-05 Eiken Kagaku Kabushiki Kaisha Process for synthesizing nucleic acid
AU2878200A (en) 1999-02-11 2000-08-29 Schepens Eye Research Institute, Inc., The Growth medium for human corneal endothelial cells
UY27224A1 (es) 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
PE20020958A1 (es) 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
US7109208B2 (en) 2001-04-11 2006-09-19 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
JP4505228B2 (ja) 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
US6690307B2 (en) 2002-01-22 2004-02-10 Nokia Corporation Adaptive variable length coding of digital video
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
EP1541559A4 (en) 2002-07-22 2007-08-22 Asahi Kasei Pharma Corp 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE
CA2400996A1 (en) 2002-09-03 2004-03-03 Lisa Mckerracher 1,4-substituted cyclohexane derivatives
US7160894B2 (en) 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
WO2005003101A2 (en) 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
WO2005039564A1 (en) 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
WO2005034866A2 (en) 2003-10-06 2005-04-21 Glaxo Group Limited Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors
ES2387780T3 (es) 2003-10-06 2012-10-01 Glaxosmithkline Llc Preparación de azabencimidazoles 1,6-disustituidos como inhibidores de quinasas
JP2007507547A (ja) 2003-10-06 2007-03-29 グラクソ　グループ　リミテッド キナーゼ阻害剤としての１，７−二置換アザベンゾイミダゾールの調製
JP2007015928A (ja) 2003-10-15 2007-01-25 Ube Ind Ltd 新規オレフィン誘導体
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
CA2556589A1 (en) 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
AR049333A1 (es) 2004-04-02 2006-07-19 Vertex Pharma Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas.
WO2006057270A1 (ja) 2004-11-26 2006-06-01 Asahi Kasei Pharma Corporation 含窒素３環化合物
CA2621181C (en) 2005-08-30 2011-04-19 Asahi Kasei Pharma Corporation 5-isoquinolinesulfonamide compounds
WO2009028631A1 (ja) * 2007-08-29 2009-03-05 Senju Pharmaceutical Co., Ltd. 角膜内皮細胞接着促進剤
EP2249800B1 (en) * 2008-02-04 2024-04-17 Jeffrey L. Goldberg Iron magnetic cells for localizing delivery and eye tissue repair
US8606848B2 (en) 2009-09-10 2013-12-10 Opentv, Inc. Method and system for sharing digital media content
WO2011080984A1 (en) * 2009-12-29 2011-07-07 Senju Pharmaceutical Co., Ltd. Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
JP5835693B2 (ja) * 2010-02-05 2015-12-24 株式会社角膜再生研究所 角膜内皮細胞の培養方法、移植用角膜内皮細胞シートの製造方法および角膜内皮細胞培養キット
EP2547082B1 (en) 2010-03-08 2019-06-26 Nec Corporation Mobile communication terminal apparatus, method for controlling power consumption of mobile communication terminal apparatus, and recording medium
KR102124149B1 (ko) 2010-05-12 2020-06-18 인터디지탈 매디슨 페이튼트 홀딩스 통합된 유효성 맵 코딩을 위한 방법 및 장치
ES2897740T3 (es) * 2011-12-28 2022-03-02 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
US9616101B2 (en) * 2012-07-06 2017-04-11 Kyoto Prefectural Public University Corporation Differentiation marker and differentiation control of eye cell
US10017735B2 (en) 2012-07-18 2018-07-10 Singapore Health Services Pte Ltd Cell culture of corneal endothelial cells
US10174284B2 (en) * 2012-09-07 2019-01-08 Jcr Pharmaceuticals Co., Ltd. Medium, for culturing corneal endothelial cells, containing conditioned medium from mesenchymal stem cells
WO2015072580A1 (ja) * 2013-11-14 2015-05-21 学校法人同志社 細胞増殖促進または細胞障害抑制による角膜内皮治療薬
JP2016077450A (ja) 2014-10-15 2016-05-16 タツタ電線株式会社 医療用チューブ
EP3416658B1 (en) 2016-02-15 2023-03-22 Kyoto Prefectural Public University Corporation Human functional corneal endothelial cell and application thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013051722A1 (ja) 2011-10-06 2013-04-11 学校法人 慶應義塾 角膜内皮細胞の製造方法
WO2015016371A1 (ja) 2013-07-30 2015-02-05 京都府公立大学法人 角膜内皮細胞マーカー

Also Published As

Publication number Publication date
WO2017141926A1 (en) 2017-08-24
US20260034177A1 (en) 2026-02-05
JP2019510509A (ja) 2019-04-18
JP2020072753A (ja) 2020-05-14
EP4218773A1 (en) 2023-08-02
JP2026012325A (ja) 2026-01-23
EP3416658B1 (en) 2023-03-22
JP2026021433A (ja) 2026-02-10
US20190083543A1 (en) 2019-03-21
PL3416658T3 (pl) 2023-09-04
JP7453669B2 (ja) 2024-03-21
JP2020073602A (ja) 2020-05-14
ES2947826T3 (es) 2023-08-21
US20210046124A1 (en) 2021-02-18
JP6954682B2 (ja) 2021-10-27
JP2024019306A (ja) 2024-02-08
EP3416658A1 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
JP6954682B2 (ja) ヒト機能性角膜内皮細胞およびその応用
JP6599334B2 (ja) 血中循環腫瘍細胞に関する方法およびアッセイ
Kim et al. Upregulated stromal cell-derived factor 1 (SDF-1) expression and its interaction with CXCR4 contribute to the pathogenesis of severe pterygia
Vu-Phan et al. The thyroid cancer PAX8–PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype
US20250123297A1 (en) Supermere Nanoparticles and Methods of Isolation and Use Thereof
Cai et al. Secretory phosphoprotein 1 secreted by fibroblast-like synoviocytes promotes osteoclasts formation via PI3K/AKT signaling in collagen-induced arthritis
Tang et al. CDC42 deficiency leads to endometrial stromal cell senescence in recurrent implantation failure
Lyu et al. Protein kinase A inhibitor H89 attenuates experimental proliferative vitreoretinopathy
JP2026027335A (ja) ヒト機能性角膜内皮細胞およびその応用
Hu et al. Endometrial BMP2 deficiency impairs ITGB3-mediated trophoblast invasion in women with repeated implantation failure
US20200247854A1 (en) Pharmaceutical composition for preventing or treating neurodegenerative disease comprising nckap1 protein or gene encoding same
US20240255520A1 (en) Hla-deleted glomerular endothelial cells and diagnostic method using thereof
HK40097456A (en) Human functional corneal endothelial cell and application thereof
US20220268780A1 (en) Methods of predicting endometrial receptivity
CN103820528B (zh) Reelin及其拮抗剂在骨髓瘤患者分期及预后中的新应用
US20260124250A1 (en) Methods for selecting cultured corneal endothelial cells
Roozitalab The effect of DCIS-associated myoepithelial cells on macrophage phenotype–drivers of DCIS progression
Hayden et al. Modulation of the tumour promoting functions of cancer associated fibroblasts by phosphodiesterase type 5 inhibition increases the efficacy of chemotherapy in human preclinical models of esophageal adenocarcinoma
WO2024158290A2 (en) Methods for selecting cultured corneal endothelial cells
Parkes-Reed Endometrial cancer cell lines as a model for metastasis
CN105256064B (zh) Csf2基因及其表达产物的新用途
Weiss et al. Schwann cell plasticity regulates neuroblastic tumor cell differentiation
Wamsley The Roles of NF-κB, Activin, and Sphingosine-1-Phosphate in Promoting Non-Small Cell Lung Cancer-Initiating Cell Phenotypes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211228

R150 Certificate of patent or registration of utility model

Ref document number: 7008337

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250